These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 27449920)

  • 1. QbD implementation and Post Approval Lifecycle Management (PALM).
    Ohage E; Iverson R; Krummen L; Taticek R; Vega M
    Biologicals; 2016 Sep; 44(5):332-40. PubMed ID: 27449920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introduction to the application of QbD principles for the development of monoclonal antibodies.
    Finkler C; Krummen L
    Biologicals; 2016 Sep; 44(5):282-90. PubMed ID: 27546184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Process characterization and Design Space definition.
    Hakemeyer C; McKnight N; St John R; Meier S; Trexler-Schmidt M; Kelley B; Zettl F; Puskeiler R; Kleinjans A; Lim F; Wurth C
    Biologicals; 2016 Sep; 44(5):306-18. PubMed ID: 27464992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishing a control system using QbD principles.
    Kepert JF; Cromwell M; Engler N; Finkler C; Gellermann G; Gennaro L; Harris R; Iverson R; Kelley B; Krummen L; McKnight N; Motchnik P; Schnaible V; Taticek R
    Biologicals; 2016 Sep; 44(5):319-31. PubMed ID: 27430904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of QbD risk assessment tools and overall risk management.
    Kelley B; Cromwell M; Jerkins J
    Biologicals; 2016 Sep; 44(5):341-51. PubMed ID: 27461127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of critical quality attributes for monoclonal antibodies using quality by design principles.
    Alt N; Zhang TY; Motchnik P; Taticek R; Quarmby V; Schlothauer T; Beck H; Emrich T; Harris RJ
    Biologicals; 2016 Sep; 44(5):291-305. PubMed ID: 27461239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical product development: A quality by design approach.
    Pramod K; Tahir MA; Charoo NA; Ansari SH; Ali J
    Int J Pharm Investig; 2016; 6(3):129-38. PubMed ID: 27606256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards the implementation of quality by design to the production of therapeutic monoclonal antibodies with desired glycosylation patterns.
    del Val IJ; Kontoravdi C; Nagy JM
    Biotechnol Prog; 2010; 26(6):1505-27. PubMed ID: 20665659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated Application of Quality-by-Design Principles to Drug Product Development: A Case Study of Brivanib Alaninate Film-Coated Tablets.
    Badawy SI; Narang AS; LaMarche KR; Subramanian GA; Varia SA; Lin J; Stevens T; Shah PA
    J Pharm Sci; 2016 Jan; 105(1):168-81. PubMed ID: 26852852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Summary of the EMA Joint Regulators/Industry QbD workshop (London, UK; 28-29 January 2014).
    Cook G; France G; Holte Ø; Lorenti G; Tainsh D
    PDA J Pharm Sci Technol; 2016; 70(2):163-76. PubMed ID: 26797977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality by design (QbD) approaches in current pharmaceutical set-up.
    Mishra V; Thakur S; Patil A; Shukla A
    Expert Opin Drug Deliv; 2018 Aug; 15(8):737-758. PubMed ID: 30044646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of quality by design principles to the development and technology transfer of a major process improvement for the manufacture of a recombinant protein.
    Looby M; Ibarra N; Pierce JJ; Buckley K; O'Donovan E; Heenan M; Moran E; Farid SS; Baganz F
    Biotechnol Prog; 2011; 27(6):1718-29. PubMed ID: 21948302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Quality by design approaches for pharmaceutical development and manufacturing of Chinese medicine].
    Xu B; Shi XY; Wu ZS; Zhang YL; Wang Y; Qiao YJ
    Zhongguo Zhong Yao Za Zhi; 2017 Mar; 42(6):1015-1024. PubMed ID: 29027410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical quality by design: product and process development, understanding, and control.
    Yu LX
    Pharm Res; 2008 Apr; 25(4):781-91. PubMed ID: 18185986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solving the Global Continual Improvement and Innovation Challenge: How an Effective Pharmaceutical Quality System Can Transform Post-Approval Change Management.
    Vinther A; Ramnarine E
    PDA J Pharm Sci Technol; 2019; 73(5):517-521. PubMed ID: 31420505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling in the quality by design environment: Regulatory requirements and recommendations for design space and control strategy appointment.
    Djuris J; Djuric Z
    Int J Pharm; 2017 Nov; 533(2):346-356. PubMed ID: 28579542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality by Design risk assessments supporting approved antibody products.
    Kelley B
    MAbs; 2016; 8(8):1435-1436. PubMed ID: 27618387
    [No Abstract]   [Full Text] [Related]  

  • 18. Latent variable modeling to assist the implementation of Quality-by-Design paradigms in pharmaceutical development and manufacturing: a review.
    Tomba E; Facco P; Bezzo F; Barolo M
    Int J Pharm; 2013 Nov; 457(1):283-97. PubMed ID: 24016743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analytical Method Lifecycle Management in Pharmaceutical Industry: a Review.
    Volta E Sousa L; Gonçalves R; Menezes JC; Ramos A
    AAPS PharmSciTech; 2021 Apr; 22(3):128. PubMed ID: 33835304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roadmap for implementation of quality by design (QbD) for biotechnology products.
    Rathore AS
    Trends Biotechnol; 2009 Sep; 27(9):546-53. PubMed ID: 19647883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.